NASDAQ: GLUE

Company Deals

Monte Rosa Therapeutics and Novartis Partner on Degrader Development

Fineline Cube Sep 16, 2025

Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE) announced today a new collaboration with Novartis (NYSE: NVS)...

Company Deals

Monte Rosa Therapeutics Strikes Licensing Deal with Novartis for VAV1 Degraders

Fineline Cube Oct 29, 2024

US-based Monte Rosa Therapeutics (NASDAQ: GLUE) has entered into a licensing agreement with Swiss pharmaceutical...

Company Drug

Novo Nordisk semaglutide Alzheimer’s biomarkers fail primary endpoint

Company Medical Device

Acotec V-otter Microcatheter Secures NMPA Approval for TACE Procedures

Company Deals

Youjia-Bio Tongee-Medical Nucleic-Acid-Drug Partnership Targets Diabetes

Company Drug

Fosun-Pharma FXS0887 ATR-Inhibitor Gets NMPA Phase 1 Nod